A Dose Block-Randomized, Double-Blinded, Placebo-Controlled, Single-Dosing, Dose Escalation Phase I Clinical Trial to Evaluate Tolerability, Safety and Pharmacodynamics of BB-rB1 (recombinant batroxobin) in Healthy Volunteers
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Recombinant batroxobin (Primary)
- Indications Haemorrhage
- Focus Adverse reactions
- Sponsors BioBud
- 05 Jul 2018 Results (n=24) published in the Clinical Drug Investigation.
- 15 Dec 2017 New trial record